Key Outcomes: Novel immunology assets advancing, with JANX011 entering first-in-human testing and TREMFYA, Nemluvio showing durable 3‑year disease control without new safety issues Strong late-stage data in niche immune/neurology: remibrutinib hits P3 endpoint across CIndU subtypes and VYVGART improves ocular MG symptoms by week 4, supporting label-expansion filings Obesity and cardio‑metabolic focus intensifies: UBT251 achieves […]

Key Outcomes: Venglustat delivered a pivotal P3 win in GD3 with strong neurological benefit and global filing plans, while Fabry development is uncertain after PERIDOT missed its primary endpoint FDA activity was strong, with Optune Pax approved as a long‑awaited new option in locally advanced pancreatic cancer and oveporexton granted priority review as a potential […]

Key Outcomes: Ophthalmology expansion: Eylea 8 mg gained EU approval for macular edema following RVO, demonstrating comparable efficacy to 2 mg with longer dosing intervals, reinforcing the Bayer–Regeneron retina franchise Oncology advancements: Multiple KRAS-targeted programs progressed, with D3 Bio securing dual FDA INDs (G12D, G12C), and first patient dosing achieved by PAQ Therapeutics and Argo […]